A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas

A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas

Abstract Background Cell-based  immunotherapy shows the therapeutic potential in sarcomas, in addition to angiogenesis-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI). Multi-antigen stimulated cell therapy-I (MASCT-I) technology is a sequential immune cell therapy for...

Full description

Bibliographic Details
Main Authors: Yan Zhou, Mei Li, Bing Zhang, Cheng Yang, Yaling Wang, Shuier Zheng, Lina Tang, Chenliang Zhou, Guowei Qian, Yujing Huang, Wenxi Yu, Hongtao Li, Yonggang Wang, Aina He, Zan Shen, Jianjun Zhang, Xiaoshuang Li, Qingcheng Yang, Haiyan Hu, Yang Yao
Format: Article
Language:English
Published: BMC 2023-11-01
Series:BMC Medicine
Subjects:
Cell-based immunotherapy
MASCT-I
Camrelizumab
Apatinib
Sarcoma
Online Access:https://doi.org/10.1186/s12916-023-03132-x

Internet

https://doi.org/10.1186/s12916-023-03132-x

Similar Items